The innovation of a new therapeutic prospect of Idiopathic Pulmonary Fibrosis (IPF), with the novel use of a commonly used drug doxycycline (Ind Jr Chest Dis Allied Sci 2007; 49:180, Lung India 2009; 26: 81-85) (Patent applied PCT no.: 278 / DEL / 2007).
In the face of virtually no treatment available for treating IPF, the innovation has a special significance. It needs a detailed study to forward a stronger evidence – unfortunately this is pending for dearth of resources. The institute is sincerely trying to mobilize resources to do a proper double blind placebo controlled trial.